Head-to-head · WeighScore
Liberty vs Zealthy
The verdict
Liberty takes it — 61/100 to 46.7/100.
Liberty grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Liberty (Liberty Health) is a nationwide online weight-loss and wellness service offering compounded GLP-1 sourced from FDA-registered 503B outsourcing facilities.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Liberty | Zealthy |
|---|---|---|
| WeighScore | 61/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #304 | #496 |
| Semaglutide | $199/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $299/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #304 · C
Strengths
- Compounded GLP-1 sourced from FDA-registered 503B outsourcing facilities, a stricter standard than the 503A pharmacies many competitors use
- Transparent flat pricing: compounded semaglutide $199/mo (about $171/mo on a 3-month supply) and tirzepatide $299/mo
- Nationwide in all 50 states with free discreet shipping, 24/7 support, and FSA/HSA acceptance
- Multi-vertical menu beyond weight loss (low-dose microdosing, NAD+, sermorelin, metformin) for patients who want bundled wellness care
Where it loses points
- Does not name its specific compounding pharmacy partner, only that it is a 503B facility
- Tirzepatide at $299/mo is mid-market rather than the cheapest option among compounded providers
- Generic corporate branding (Liberty Health) with limited public detail on the operating entity
- Compounded medication only — no brand-name or insurance-covered GLP-1 path
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.